Phospho-FOXM1 (Ser35) Antibody - #AF4458

Fig. 6 TIS21/FoxM1 was essential for TRIM6-inhibited CRC cell proliferation and cell cycle progression. a, Sw620 cells were transfected with plasmids expressing TRIM6, TIS21 or vector. Overexpression of TRIM6 or TIS21 was confirmed by western blotting. B-F, Sw620 cells were divided into four groups: Vector (cells transfected with vector), TRIM6 (cells transfected with plasmid expressing TRIM6), TIS21 (cells transfected with plasmid expressing TIS21) and TRIM6 + TIS21 (cells transfected with plasmid expressing TRIM6 and plasmid expressing TIS21). CCK-8 (b), BrdU (c), flow cytometry analyses (d) and western blotting (e, f) were performed to determine the effects of TRIM6 and TIS21 on the proliferation, cell cycle distribution and relative protein expression, respectively. F, HCT-8 cells were transfected with plasmids expressing FoxM1 or vector. Overexpression of TRIM6 or TIS21 was confirmed by western blotting. G-J, HCT-8 cells were divided into four groups: Vector+shNC (cells treated with vector and control shRNA), Vector+shTRIM6 (cells treated with vector and TRIM6 shRNA), FoxM1 + shNC (cells treated with plamid expressing FoxM1 and control shRNA) and FoxM1 + shTRIM6 (cells treated with plamid expressing FoxM1 and TRIM6 shRNA). CCK-8 (g), BrdU (h), flow cytometry analyses (i) and western blotting (j) were performed to determine the effects of FoxM1 overexpression and TRIM6 knockdown on the proliferation, cell cycle distribution and relative protein expression, respectively. *P < 0.05, **P < 0.05, ***P < 0.001